Parametera | Cohort 1 (n = 23) | Cohort 2 (n = 75) | Cohort 3 (n = 27) | Total (N = 125) |
---|---|---|---|---|
Age, years | ||||
Mean (SD) | 65.6 (13.7) | 61.8 (13.2) | 60.1 (13.9) | 62.1 (13.5) |
Median (range) | 67 (32–82) | 65 (19–83) | 62 (28–79) | 65 (19–83) |
Sex | ||||
Female, n (%) | 19 (82.6) | 47 (62.7) | 17 (63.0) | 83 (66.4) |
Male, n (%) | 4 (17.4) | 28 (37.3) | 10 (37.0) | 42 (33.6) |
Immunodeficiency diagnosisb | ||||
PID diagnosis, n (%) | 10 (43.5) | 32 (42.7) | 19 (70.4) | 61 (48.8) |
CVID | 5 (50.0) | 24 (75.0) | 14 (73.7) | 43 (70.5) |
Isolated IG subclass deficiency | 0 | 1 (3.1) | 2 (10.5) | 3 (4.9) |
IgG2 deficiency | 0 | 1 (3.1) | 2 (10.5) | 3 (4.9) |
Specific antibody deficiency with normo- or hypogammaglobulinemia | 0 | 1 (3.1) | 1 (5.3) | 2 (3.3) |
Unclassified antibody deficiency | 2 (20.0) | 3 (9.4) | 0 | 5 (8.2) |
Combined IgA/IgG subclass deficiency | 1 (10.0) | 0 | 0 | 1 (1.6) |
Other | 2 (20.0) | 6 (18.8) | 2 (10.5) | 10 (16.4) |
SID associated with, n (%) | 13 (56.5) | 44 (58.7) | 8 (29.6) | 65 (52.0) |
Chronic lymphocytic leukemia | 3 (23.1) | 27 (61.4) | 6 (75.0) | 36 (55.4) |
Multiple myeloma | 2 (15.4) | 2 (4.5) | 0 | 4 (6.2) |
Post-allogeneic HSCT | 1 (7.7) | 0 | 0 | 1 (1.5) |
Other | 7 (53.8) | 15 (34.1) | 2 (25.0) | 24 (36.9) |